Iveric Bio to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

Rhea-AI Summary

Iveric Bio, a biopharmaceutical company focused on retinal diseases, announced that Pravin U. Dugel, M.D., its President, will participate in a fireside chat at B. Riley Securities' Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 9:00 a.m. ET. The event will be accessible via live webcast on the Iveric Bio website, with an archived replay available for 30 days following the conference. Iveric Bio aims to develop innovative treatments for retinal diseases, including age-related macular degeneration.

PARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a fireside chat at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022, at 9:00 a.m. Eastern Time.

Investors and the general public are invited to access the live webcast of the fireside chat on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the fireside chat will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.

About Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the “Risk Factors” section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005963/en/

Investor Contact:

Kathy Galante

Senior Vice President, Investor Relations

kathy.galante@ivericbio.com

or

Media Contact:

Jeannie Neufeld

Senior Director, Public Relations and Communications

jeannie.neufeld@ivericbio.com

Source: IVERIC bio, Inc.

FAQ

When is Iveric Bio's fireside chat at the B. Riley Securities' conference?

Iveric Bio's fireside chat is scheduled for April 28, 2022, at 9:00 a.m. ET.

How can I access the Iveric Bio fireside chat?

The fireside chat can be accessed via a live webcast on Iveric Bio's website.

Will there be a replay of Iveric Bio's fireside chat?

Yes, an archived replay of the fireside chat will be available for at least 30 days after the event.

What is the focus of Iveric Bio's research?

Iveric Bio focuses on developing treatments for retinal diseases with significant unmet medical needs.

What is the stock symbol for Iveric Bio?

The stock symbol for Iveric Bio is ISEE.